RIGL Earnings

RIGL reported its earnings on 2026-05-05, showcasing a revenue of 58.82M against an estimate of 60.26M, resulting in a -2.39% surprise. The EPS was 0.44, surpassing the expected 0.74 by -40.54%. The stock experienced a -5.06% price change on the earnings day and a -6.73% change over the next five days, reflecting market reactions to the results.

Following RIGL's earnings announcement on 2026-05-05, the stock price moved by -5.06% on the day of the release. Over the subsequent five days, it saw a -6.73% change. Historically, RIGL's stock price tends to shift by an average of -2.15% in the 10 days leading up to earnings and 11.35% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate RIGL's annual revenue to reach 65.75M, while the EPS is projected at 1.02. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between RIGL's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, RIGL's stock price typically moves by -2.15% in the 10 days before its earnings and 11.35% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of 1.02 and revenue of 65.75M.

The earnings call highlights strong financial performance with significant year-over-year sales growth across key products, despite a slight net income decline due to higher R&D and operational expenses. The Q&A section reveals management's strategic focus on hematology/oncology, with promising developments for R289. Although some details were unclear, the overall sentiment is positive, supported by a robust revenue increase and strategic product focus. Given the company's small-cap status, the stock is likely to react positively, falling into the 2% to 8% range over the next two weeks.